$992 Million is the total value of Vivo Capital, LLC's 44 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 85.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRNX | New | Crinetics Pharmaceuticals Inc | $108,646,000 | – | 3,792,169 | +100.0% | 10.95% | – |
| SVA | New | Sinovac Biotech Ltd | $44,958,000 | – | 5,900,000 | +100.0% | 4.53% | – |
| ARWR | Buy | Arrowhead Pharmaceuticals In | $44,637,000 | +72.7% | 2,328,475 | +22.6% | 4.50% | +35.1% |
| AMRS | Buy | Amyris, Inc. | $44,266,000 | +145.1% | 5,575,118 | +97.2% | 4.46% | +91.7% |
| KALV | Buy | KalVista Pharmaceuticals, Inc. | $30,051,000 | +1132.1% | 1,359,149 | +352.6% | 3.03% | +864.6% |
| XENE | New | Xenon Pharmaceuticals Inc | $18,552,000 | – | 1,405,476 | +100.0% | 1.87% | – |
| Buy | Nabriva Therapeutics Plc | $17,872,000 | +26.1% | 6,619,190 | +62.5% | 1.80% | -1.4% | |
| ACER | New | Acer Therapeutics Inc | $17,442,000 | – | 565,579 | +100.0% | 1.76% | – |
| OBSV | Buy | Obseva SA | $16,897,000 | +20.6% | 937,147 | +1.3% | 1.70% | -5.7% |
| GLMD | Buy | Galmed Pharmaceuticals Ltd | $11,563,000 | +22.6% | 851,492 | +7.4% | 1.16% | -4.1% |
| KNSA | Buy | Kiniksa Pharmaceuticals-A | $6,754,000 | +109.2% | 264,878 | +42.4% | 0.68% | +63.7% |
| ARVN | New | Arvinas Holding Co LLC | $5,061,000 | – | 300,000 | +100.0% | 0.51% | – |
| GTXI | New | GTX Inc | $165,000 | – | 105,043 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.